67 results about "CD146" patented technology

Mesenchymal precursors cells have been isolated from perivascular niches from a range of tissues utilizing a perivascular marker. A new mesenchymal precursor cell phenotype is described characterized by the presence of the perivascular marker 3G5, and preferably also alpha smooth muscle actin together with early developmental markers such as STRO-1 and CD146 / MUC18. The perivascular mesenchymal precursor cell is shown to induce neovascularisation and improvement in cardiac function. Suitable administration of preparations of the mesenchymal precursor cells are useful for treatment of cardiovascular diseases, cerebrovascular diseases and peripheral vascular diseases.

The invention provides a method of producing human immature dental pulp stem cells (hIDPSCs) expressing CD44 and CD13 and lacking expression of CD146. The invention also provides compositions for usein the treatment of a neurological disease or condition selected from the group consisting of Parkinson's disease (PD), multiple sclerosis, 5 amyotrophic lateral sclerosis (ALS), stroke, autoimmune encephalomyelitis, diabetic neuropathy, glaucomatous neuropathy, Alzheimer's disease, Huntington's disease (HD), autism, schizophrenia, stroke, ischemia, a motor disorder, and a convulsive disorder.

The present invention provides a combination of compositions comprising i) a composition comprising I) a population of T cells, NK cells or cytotoxic immune effector cells comprising a chimeric antigen receptor specific for a stem cell antigen and / or, II) alpha) a population of T cells, NK cells or cytotoxic immune effector cells comprising a chimeric antigen receptor specific for a tag of a tagged polypeptide, wherein said tagged polypeptide binds specifically to a stem cell antigen, and beta) said tagged polypeptide, and ii) a composition comprising a) a population of CD34+ hematopoietic stem cells, and b) one or more accessory or contributory cell populations selected from the group consisting of myeloid cell lineages expressing CD14, CD11b, CD11c, CD123, CD33; CD36; CD47, CD66b, CD235a, CD146 and CD326. A method applying these compositions to a subject in need thereof are also provided.

The invention relates to a full sealed pipelined protein purification system and a method of a purification sterile apyrogeneity humanization anti-CD146 monoclonal antibody based on the full sealed pipelined protein purification system.

The CD146 albumen molecules or the cell giving expression to CD146 albumen are utilized to filter out biomolecule possessing the CD146 binding activity. Using the cell giving expression to CD146 molecules natively detects whether the biomolecule possessing the CD146 binding activity can restrain or activate growth of the cell or not. The medicament filtered by the invention can be applied to prevent, diagnose and cure the disease related to the angiogenesis as well as can be used as new type medicament for abortion and contraception to control population.

The invention relates to an application of CD146 and its antibody in diagnosis and treatment of triple negative breast cancer. The CD146 being a novel target of the triple negative breast cancer is proposed for the first time, and the anti-CD146 antibody may become a novel targeted drug for the treatment of like diseases, so the invention provides the application of the CD146 or the anti-CD146 antibody or functional forms of the antibody in the preparation of drugs for diagnosing and / or treating the triple negative breast cancer. The CD146 molecule is highly specifically expressed in triple negative breast cancer tissues, induces the transformation of epithelial cells of tumor cells into interstitial cells, and promotes the invasion and migration of tumors, so the action mechanism of the CD146 antibody in the treatment of the triple negative breast cancer is mainly to inhibit the interstitial cell characteristics of the triple negative breast cancer cells and reduce the metastasis andinvasion ability. Compared with conventional chemotherapeutic drugs, the anti-CD146 antibody has the advantages of small side effects, clear target and no systemic side effects.